$MGTX
MeiraGTx Holdings plc Stock $mgtx

$mgtx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000155837023009274 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$3.540M	$3.334M
YoY Change	-67.1%	-40.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.39M	$12.77M
YoY Change	17.78%	13.35%
% of Gross Profit
Research & Development	$19.94M	$22.32M
YoY Change	-16.93%	-3.36%
% of Gross Profit
Depreciation & Amortization	$3.247M	$3.092M
YoY Change	55.73%	45.99%
% of Gross Profit
Operating Expenses	$32.33M	$35.09M
YoY Change	-6.35%	2.12%
Operating Profit	-$28.79M	-$31.76M
YoY Change	21.16%	10.53%
Interest Expense	$3.355M	$3.060M
YoY Change	3991.46%	3874.03%
% of Operating Profit
Other Income/Expense, Net	-$1.000K	$10.00K
YoY Change	-100.48%	-97.18%
Pretax Income	-$29.58M	-$30.36M
YoY Change	-12.93%	-2.19%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$29.58M	-$30.36M
YoY Change	-12.93%	-2.19%
Net Earnings / Revenue	-835.62%	-910.74%
Basic Earnings Per Share	-$0.53	-$0.62
Diluted Earnings Per Share	-$0.53	-$0.62
COMMON SHARES
Basic Shares Outstanding	59.50M	48.67M
Diluted Shares Outstanding	55.35M	48.64M

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$92.77M	$68.78M
YoY Change	28.66%	-39.55%
Cash & Equivalents	$92.77M	$68.78M
Short-Term Investments
Other Short-Term Assets	$1.547M	$1.561M
YoY Change	-53.54%	-21.32%
Inventory
Prepaid Expenses	$8.108M	$6.981M
Receivables	$32.69M	$36.30M
Other Receivables	$8.026M	$7.857M
Total Short-Term Assets	$143.1M	$121.5M
YoY Change	37.1%	-15.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$114.0M	$112.6M
YoY Change	24.75%	33.91%
Goodwill
YoY Change
Intangibles	$1.252M	$1.295M
YoY Change	-15.06%	-22.36%
Long-Term Investments	$6.326M	$6.326M
YoY Change	-4.96%	-4.96%
Other Assets	$1.465M	$1.428M
YoY Change	-2.66%	-11.25%
Total Long-Term Assets	$167.1M	$166.7M
YoY Change	12.88%	15.12%
TOTAL ASSETS
Total Short-Term Assets	$143.1M	$121.5M
Total Long-Term Assets	$167.1M	$166.7M
Total Assets	$310.3M	$288.1M
YoY Change	22.9%	0.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$28.50M	$29.76M
YoY Change	57.35%	60.86%
Accrued Expenses	$24.89M	$31.07M
YoY Change	5.59%	34.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$71.80M	$81.10M
YoY Change	6.37%	23.82%
LONG-TERM LIABILITIES
Long-Term Debt	$71.57M	$71.30M
YoY Change
Other Long-Term Liabilities	$43.17M	$45.32M
YoY Change	0.86%	-25.35%
Total Long-Term Liabilities	$114.7M	$116.6M
YoY Change	168.07%	92.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$71.80M	$81.10M
Total Long-Term Liabilities	$114.7M	$116.6M
Total Liabilities	$186.7M	$197.9M
YoY Change	69.01%	56.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$530.1M	-$500.6M
YoY Change	30.7%	34.71%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$123.5M	$90.22M
YoY Change
Total Liabilities & Shareholders Equity	$310.3M	$288.1M
YoY Change	22.9%	0.16%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$29.58M	-$30.36M
YoY Change	-12.93%	-2.19%
Depreciation, Depletion And Amortization	$3.247M	$3.092M
YoY Change	55.73%	45.99%
Cash From Operating Activities	-$29.01M	-$37.40M
YoY Change	4.33%	350.6%
INVESTING ACTIVITIES
Capital Expenditures	$4.975M	$8.605M
YoY Change	-135.54%	-30.94%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$4.975M	-$8.605M
YoY Change	-64.46%	-30.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	57.95M	-1.231M
YoY Change		-52.32%
NET CHANGE
Cash From Operating Activities	-29.01M	-37.40M
Cash From Investing Activities	-4.975M	-8.605M
Cash From Financing Activities	57.95M	-1.231M
Net Change In Cash	23.96M	-47.24M
YoY Change	-157.31%	102.36%
FREE CASH FLOW
Cash From Operating Activities	-$29.01M	-$37.40M
Capital Expenditures	$4.975M	$8.605M
Free Cash Flow	-$33.99M	-$46.01M
YoY Change	146.16%	121.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1335000
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59500314
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68784000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	115516000
CY2023Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	36298000
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	21334000
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6981000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8133000
CY2023Q1	mgtx	Tax Incentive Receivable TaxIncentiveReceivable	7857000
CY2022Q4	mgtx	Tax Incentive Receivable TaxIncentiveReceivable	7689000
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1561000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1667000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	121481000
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48638151
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44501314
CY2023Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2022Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2023Q1	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2022Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001735438
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48477209
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48477209
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38520
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	MeiraGTx Holdings plc
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1448305
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	450 East 29th Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	14th Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10016
CY2023Q1	dei	City Area Code CityAreaCode	646
CY2022Q4	us-gaap	Assets Current AssetsCurrent	154339000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112580000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109266000
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1295000
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	860-7985
CY2023Q1	dei	Security12b Title Security12bTitle	Ordinary Shares,$0.00003881 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	MGTX
CY2023Q1	mgtx	In Process Research And Development InProcessResearchAndDevelopment	752000
CY2022Q4	mgtx	In Process Research And Development InProcessResearchAndDevelopment	742000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1428000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1402000
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	6326000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	6326000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19427000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20109000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24851000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24718000
CY2023Q1	us-gaap	Assets Assets	288140000
CY2022Q4	us-gaap	Assets Assets	318237000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	29755000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16616000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31067000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39818000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4018000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3884000
CY2023Q1	mgtx	Deferred Revenue Related Party Current DeferredRevenueRelatedPartyCurrent	13693000
CY2022Q4	mgtx	Deferred Revenue Related Party Current DeferredRevenueRelatedPartyCurrent	15123000
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2571000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6631000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	81104000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	82072000
CY2023Q1	mgtx	Deferred Revenue Related Party Noncurrent DeferredRevenueRelatedPartyNoncurrent	26425000
CY2022Q4	mgtx	Deferred Revenue Related Party Noncurrent DeferredRevenueRelatedPartyNoncurrent	27436000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16453000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17331000
CY2023Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2238000
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2179000
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	189000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	186000
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	71301000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	71033000
CY2023Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	208000
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	262000
CY2023Q1	us-gaap	Liabilities Liabilities	197918000
CY2022Q4	us-gaap	Liabilities Liabilities	200499000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003881
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003881
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1288327750
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1288327750
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48686263
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48477209
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	2000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	587094000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	581893000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3694000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6047000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-500568000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-470204000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	90222000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	117738000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	288140000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	318237000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3334000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5633000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12772000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11268000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22322000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23099000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	35094000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	34367000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-31760000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28734000
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3857000
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2647000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	545000
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	16000
CY2023Q1	us-gaap	Interest Expense InterestExpense	3060000
CY2022Q1	us-gaap	Interest Expense InterestExpense	77000
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	54000
CY2022Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	397000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30364000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31045000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2353000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1932000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32717000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29113000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30364000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31045000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48638151
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44501314
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	117738000
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5201000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2353000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30364000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	90222000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	185401000
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4996000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1932000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31045000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	161284000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-30364000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-31045000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6432000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7578000
CY2023Q1	mgtx	Cash Flow Effect On Foreign Currency Loss CashFlowEffectOnForeignCurrencyLoss	-3857000
CY2022Q1	mgtx	Cash Flow Effect On Foreign Currency Loss CashFlowEffectOnForeignCurrencyLoss	2647000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3092000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2118000
CY2023Q1	mgtx	Cash Flow Effect Of Changes In Right Of Use Assets And Liabilities CashFlowEffectOfChangesInRightOfUseAssetsAndLiabilities	-24000
CY2022Q1	mgtx	Cash Flow Effect Of Changes In Right Of Use Assets And Liabilities CashFlowEffectOfChangesInRightOfUseAssetsAndLiabilities	-50000
CY2023Q1	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	44000
CY2022Q1	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	42000
CY2023Q1	mgtx	Amortization Of Debt Discount AmortizationOfDebtDiscount	266000
CY2023Q1	mgtx	Cash Flow Effect On Fair Value Adjustment Of Acquisition Liability CashFlowEffectOnFairValueAdjustmentOfAcquisitionLiability	-54000
CY2022Q1	mgtx	Cash Flow Effect On Fair Value Adjustment Of Acquisition Liability CashFlowEffectOnFairValueAdjustmentOfAcquisitionLiability	-397000
CY2023Q1	mgtx	Decrease Increase In Related Party Accounts Receivable DecreaseIncreaseInRelatedPartyAccountsReceivable	-14137000
CY2022Q1	mgtx	Decrease Increase In Related Party Accounts Receivable DecreaseIncreaseInRelatedPartyAccountsReceivable	9171000
CY2023Q1	mgtx	Decrease Increase In Prepaid Expenses DecreaseIncreaseInPrepaidExpenses	1235000
CY2022Q1	mgtx	Decrease Increase In Prepaid Expenses DecreaseIncreaseInPrepaidExpenses	780000
CY2022Q1	mgtx	Decrease Increase In Tax Incentive Receivable DecreaseIncreaseInTaxIncentiveReceivable	5565000
CY2023Q1	mgtx	Decrease Increase In Other Current Assets DecreaseIncreaseInOtherCurrentAssets	136000
CY2022Q1	mgtx	Decrease Increase In Other Current Assets DecreaseIncreaseInOtherCurrentAssets	387000
CY2022Q1	mgtx	Decrease Increase In Other Assets DecreaseIncreaseInOtherAssets	-239000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	14642000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4609000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11469000
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3831000
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3334000
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5633000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37392000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8298000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8605000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12460000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8605000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12460000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	192000
CY2023Q1	mgtx	Adjustments To Additional Paid In Capital Taxes Withheld On Issuance Of Share Based Awards AdjustmentsToAdditionalPaidInCapitalTaxesWithheldOnIssuanceOfShareBasedAwards	-1231000
CY2022Q1	mgtx	Adjustments To Additional Paid In Capital Taxes Withheld On Issuance Of Share Based Awards AdjustmentsToAdditionalPaidInCapitalTaxesWithheldOnIssuanceOfShareBasedAwards	-2774000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1231000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2582000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-47228000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-23340000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	496000
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-582000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115516000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137703000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68784000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113781000
CY2023Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	3162000
CY2022Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	8567000
CY2022Q1	mgtx	Right Of Use Assets Obtained In Exchange For Lease Liabilities RightOfUseAssetsObtainedInExchangeForLeaseLiabilities	1793000
CY2022Q1	mgtx	Asset Retirement Obligations Incurred In Connection With Leases Non Cash AssetRetirementObligationsIncurredInConnectionWithLeasesNonCash	10000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1572000
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	36000
CY2023Q1	mgtx	No.Of Programs In Clinical Development No.OfProgramsInClinicalDevelopment	6
CY2023Q1	mgtx	No.Of Distinct Areas Of Unmet Medical Need No.OfDistinctAreasOfUnmetMedicalNeed	3
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-500600000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37400000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68800000
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: collaboration revenue, the accounting for research and development costs, share-based compensation, valuation of warrants, leases, asset retirement obligations and tax incentive receivable.</p>
CY2022Q4	mgtx	Accrued Expenses Incurred In Connection With Fixed Assets AccruedExpensesIncurredInConnectionWithFixedAssets	3093000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	321000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	932000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31067000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39818000
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2179000
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2081000
CY2022Q1	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	10000
CY2023Q1	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	44000
CY2022Q1	mgtx	Amortization Of Interest On Asset Retirement Obligation AmortizationOfInterestOnAssetRetirementObligation	42000
CY2023Q1	us-gaap	Asset Retirement Obligation Foreign Currency Translation Gain Loss AssetRetirementObligationForeignCurrencyTranslationGainLoss	15000
CY2022Q1	us-gaap	Asset Retirement Obligation Foreign Currency Translation Gain Loss AssetRetirementObligationForeignCurrencyTranslationGainLoss	-19000
CY2023Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2238000
CY2022Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2114000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11686179
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9339934
CY2023Q1	us-gaap	Noncurrent Assets NoncurrentAssets	166659000
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	163898000
CY2023Q1	mgtx	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	12241000
CY2022Q4	mgtx	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	13041000
CY2023Q1	mgtx	Accrued Research And Development AccruedResearchAndDevelopment	6644000
CY2022Q4	mgtx	Accrued Research And Development AccruedResearchAndDevelopment	7400000
CY2023Q1	mgtx	Accrued Liabilities Accrued Compensation And Benefits AccruedLiabilitiesAccruedCompensationAndBenefits	4901000
CY2022Q4	mgtx	Accrued Liabilities Accrued Compensation And Benefits AccruedLiabilitiesAccruedCompensationAndBenefits	9600000
CY2023Q1	mgtx	Accrued Liabilities Accrued Manufacturing Costs Expense AccruedLiabilitiesAccruedManufacturingCostsExpense	2712000
CY2023Q1	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	6326000
CY2023Q1	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	6665000
CY2022Q4	mgtx	Accrued Liabilities Accrued Manufacturing Costs Expense AccruedLiabilitiesAccruedManufacturingCostsExpense	4326000
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1716000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	732000
CY2023Q1	mgtx	Accrued Consulting Expenses AccruedConsultingExpenses	1365000
CY2022Q4	mgtx	Accrued Consulting Expenses AccruedConsultingExpenses	694000
CY2023Q1	mgtx	Accrued Expenses Incurred In Connection With Fixed Assets AccruedExpensesIncurredInConnectionWithFixedAssets	1167000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6858409
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.03
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M9D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1423340
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.59
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	48369
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.94
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8233380
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.09
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M13D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4982138
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.86
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M20D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	882
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	882
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6200000
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6200000
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6800000
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6800000
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6800000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.77
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.39
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.39
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6432000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7578000
CY2022Q1	mgtx	Excess Tax Benefit From Share Based Compensation Operating Activities1 ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1	0
CY2023Q1	mgtx	Excess Tax Benefit From Share Based Compensation Operating Activities1 ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1	0
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1400000
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	281000
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	294000
CY2023Q1	mgtx	Finance Lease Cost FinanceLeaseCost	281000
CY2022Q1	mgtx	Finance Lease Cost FinanceLeaseCost	294000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1361000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1315000
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	39000
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	38000
CY2023Q1	us-gaap	Lease Cost LeaseCost	1681000
CY2022Q1	us-gaap	Lease Cost LeaseCost	1647000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19427000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20109000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	20471000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21215000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24851000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24718000
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P175Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P175Y9M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.088
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.088
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1384000
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1370000
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1793000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4093000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5284000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5239000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4976000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1775000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2924000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24291000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3820000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	20471000
CY2023Q1	mgtx	Number Of New Material Commitments NumberOfNewMaterialCommitments	0

Files In Submission

Name	View Source	Status
mgtx-20230331_lab.xml	Edgar Link	unprocessable
0001558370-23-009274-index-headers.html	Edgar Link	pending
0001558370-23-009274-index.html	Edgar Link	pending
0001558370-23-009274.txt	Edgar Link	pending
0001558370-23-009274-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgtx-20230331.xsd	Edgar Link	pending
mgtx-20230331x10q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mgtx-20230331xex31d1.htm	Edgar Link	pending
mgtx-20230331xex31d2.htm	Edgar Link	pending
mgtx-20230331xex32d1.htm	Edgar Link	pending
mgtx-20230331xex32d2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
mgtx-20230331_def.xml	Edgar Link	unprocessable
mgtx-20230331_pre.xml	Edgar Link	unprocessable
mgtx-20230331_cal.xml	Edgar Link	unprocessable
mgtx-20230331x10q_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGTX
MeiraGTx Holdings plc Stock $mgtx

2023 Q2 Form 10-Q Financial Statement

#000155837023009274 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGTX MeiraGTx Holdings plc Stock $mgtx

2023 Q2 Form 10-Q Financial Statement

#000155837023009274 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGTX
MeiraGTx Holdings plc Stock $mgtx